GLP-1 receptor agonists (GLP-1 RAs) have demonstrated multiple cardiometabolic benefits including body weight (BW) reduction, improved glycemic control and insulin resistance, and reduction in cardiovascular event risk [4-7]. This evidence concerns the gene GLP1R and Insulin resistance.